In this episode of OncoDaily, Shushan Hovsepyan sits down with Dr. Alan Sandler, Chief Development Officer at Revolution Medicines, to discuss one of the most talked-about presentations at ASCO 2026 and the story behind Daraxonrasib.
Dr. Sandler shares how Revolution Medicines evolved from its early beginnings to becoming a leader in RAS-targeted therapies. He explains the scientific rationale behind targeting RAS-driven tumors, the challenges of drug development, and the pivotal moments that convinced the team they were on the right path.
The conversation explores the standing ovation received during the ASCO presentation, the remarkable survival benefit observed in second-line pancreatic cancer, quality-of-life improvements, ongoing first-line and adjuvant studies, and the company’s broader vision for treating RAS-addicted cancers.
Dr. Sandler also reflects on his own journey in oncology drug development and what he hopes Revolution Medicines’ legacy will be.
OncoDaily Conversations brings together leaders in oncology, research, and innovation to discuss breakthroughs that are shaping the future of cancer care.